Article

Estrogen receptor-negative/progesterone receptor-positive and her-2 negative breast cancer might no longer be classified as hormone receptor positive breast cancer

2020-12-02

Abstract excerpt

<h4>Background: </h4> The estrogen receptor (ER)-negative/progesterone receptor (PR)-positive (sPR positive) phenotype is an infrequent and independent biological entity. However, the prognosis of patients with sPR positive and her-2 negative phenotype is still controversial, and it is not always easy to decide treatment strategies for them. <h4>Methods:</h4> Patients during 2010–2014 were identified from Surveill...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 300ea30e-0d14-5e78-a88f-1cf9fd4f7af0
DOI: 10.22541/au.160689672.25060571/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Estrogen receptor-negative/progesterone receptor-positive and her-2 negative breast cancer might no longer be classified as hormone receptor positive breast cancerDOI 10.22541/au.160689672.25060571/v1Read

Estrogen Receptor-negative/progesterone Receptor-positive and Her-2 Negative Breast Cancer Might No Longer Be Classified as Hormone Receptor Positive Breast CancerSemantic proximity Read

Trends in the Incidence and Survival of Women with Hormone Receptor-Positive Breast Cancer from 1990–2019: A Large Population-Based AnalysisSemantic proximity Read

Genetic and clinical landscape of ER + /PR- breast cancer in China.Semantic proximity Read

The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.Semantic proximity Read

Risk Evaluation of Early-stage Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Patients: a Population-based Study From TaiwanSemantic proximity Read

Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapySemantic proximity Read

The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity Read

The loss of progesterone receptor predicts more aggressive biological features and worse outcomes in estrogen receptor-positive and HER2-negative inflammatory breast cancerSemantic proximity Read

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of ageSemantic proximity Read

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: a SEER Population-Based AnalysisSemantic proximity Read

HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and OutcomeSemantic proximity Read

ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.Semantic proximity Read